{rfName}
Le

Documents and Files

License and Use

Licencia

Altmetrics

Analysis of institutional authors

López-Vicario CCorresponding AuthorTitos EAuthorAlcaraz-Quiles JAuthorCasulleras MAuthorDuran-Güell MAuthorFlores-Costa RAuthorClaria JCorresponding Author

Share

March 11, 2019
Publications
>
Article
No

Leukocytes from obese individuals exhibit an impaired SPM signature

Publicated to: FASEB JOURNAL. 33 (6): 7072-7083 - 2019-06-01 33(6), DOI: 10.1096/fj.201802587R

Authors:

Lopez-Vicario, Cristina; Titos, Esther; Walker, Mary E; Walker, Mary E; Alcaraz-Quiles, Jose; Casulleras, Mireia; Duran-Guell, Marta; Flores-Costa, Roger; Perez-Romero, Noelia; Forne, Montserrat; Dalli, Jesmond; Claria, Joan
[+]

Affiliations

Biochemistry and Molecular Genetics Service, Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain - Author
Department of Biomedical Sciences, University of Barcelona, Barcelona, Spain - Author
European Fdn Study Chron Liver Failure EF CLIF, Barcelona, Spain - Author
European Foundation for the Study of Chronic Liver Failure (EF Clif), Barcelona, Spain - Author
European Foundation for the Study of Chronic Liver Failure (EF Clif), Barcelona, Spain and - Author
Gastroenterology Department, Hospital Universitari Mútua Terrassa, Terrassa, Spain - Author
Hosp Univ Mutua Terrassa, Gastroenterol Dept, Terrassa, Spain - Author
Hosp Univ Mutua Terrassa, Surg Dept, Terrassa, Spain - Author
Lipid Mediator Unit, Biochemical Pharmacology, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, United Kingdom - Author
Queen Mary Univ London, Barts & London Sch Med, William Harvey Res Inst, Lipid Mediator Unit,Biochem Pharmacol, London, England - Author
Queen Mary Univ London, Ctr Inflammat & Therapeut Innovat, London, England - Author
Surgery Department, Hospital Universitari Mútua Terrassa, Terrassa, Spain - Author
Univ Barcelona, Dept Biomed Sci, Barcelona, Spain - Author
Univ Barcelona, Inst Invest Biomed August Pi I Sunyer IDIBAPS, Hosp Clin, Biochem & Mol Genet Serv,Ctr Invest Biomed Red En, Madrid, Spain - Author
See more

Abstract

Specialized proresolving mediators (SPMs) biosynthesized from docosahexaenoic acids (DHAs) including resolvins (Rvs), protectins, and maresins are potent endogenous autacoids that actively resolve inflammation, protect organs, and stimulate tissue regeneration. Our hypothesis was that failure of resolution programs may lead to unremitting inflammation in obesity, contributing to the development of metabolic comorbidities in this condition. Obese individuals with persistent low-grade systemic inflammation showed reduced leukocyte production of the DHA-derived monohydroxy fatty acid 17- hydroxy-DHA (HDHA) and unbalanced formation of SPMs (in particular D-series Rvs) accompanied by enhanced production of proinflammatory lipid mediators such as leukotriene B4. Mechanistic studies attributed this impairment to reduced 15-lipoxygenase (LOX) activity rather than altered DHA cellular uptake. Moreover, leukocytes from obese individuals exhibited decreased 5-LOX levels and reduced 5-LOX Ser271 phosphorylation and distinct intracellular 5-LOX redistribution. However, 15-LOX appears to be the most critical factor for the deficient production of SPMs by obese leukocytes because the formation of D-series Rvs was completely rescued by incubation with the intermediate precursor 17-HDHA. These data provide proof of concept that administration of intermediate precursors of SPM biosynthesis ( e.g., 17-HDHA) could be more efficient in overriding impaired formation of these proresolving lipid mediators in conditions characterized by dysfunctional LOX activity, such as obesity.-López-Vicario, C., Titos, E., Walker, M. E., Alcaraz-Quiles, J., Casulleras, M., Durán-Güell, M., Flores-Costa, R., Pérez-Romero, N., Forné, M., Dalli, J., Clària, J. Leukocytes from obese individuals exhibit an impaired SPM signature.
[+]

Keywords

5-lipoxygenaseinflammationinsulin-resistancelipoxygenasesmembrane associationnuclear-localizationobesityomega-3-fatty-acidsphosphorylationresolutionresolvin d15-lipoxygenaseCase-control studiesDocosahexaenoic acidsGenética humanaHuman geneticsHumansInflammationInsulin-resistanceLeucòcitsLeucocytesLeukocytesLipid metabolismLipoxygenasesMembrane associationNuclear-localizationObesitatObesityOmega-3-fatty-acidsPhosphorylationProresolving lipid mediatorsResolutionResolvin d1Specialized proresolving mediator

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal FASEB JOURNAL due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2019, it was in position 9/93, thus managing to position itself as a Q1 (Primer Cuartil), in the category Biology. Notably, the journal is positioned above the 90th percentile.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 1.64. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 13, 2025)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 1.68 (source consulted: FECYT Mar 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2026-04-05, the following number of citations:

  • WoS: 50
  • Scopus: 47
  • Europe PMC: 46
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-05:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 59.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 59 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 4.
  • The number of mentions on the social network Facebook: 1 (Altmetric).
  • The number of mentions on the social network X (formerly Twitter): 1 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

[+]

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: United Kingdom.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (López Vicario, Cristina) and Last Author (Claria Enrich, Joan).

the authors responsible for correspondence tasks have been López Vicario, Cristina and Claria Enrich, Joan.

[+]

Awards linked to the item

The authors thank Anabel Martinez-Puchol (Fundacio Clinic per la Recerca Biomedica, Barcelona, Spain) for technical assistance. This study was supported by the Spanish Ministerio de Economia y Competitividad (MEC; SAF15/63674-R and PIE14/00045) under the European Regional Development Fund (ERDF). CIBEREHD is funded by the Instituto de Salud Carlos III. The authors' laboratory is a Consolidated Research Group recognized by the Generalitat de Catalunya (2017SGR1449). This study was carried out at the Center Esther Koplowitz, Institut d'investigacions Biomediques August Pi i Sunyer (IDIBAPS), which is part of the Centres de Recerca de Catalunya (CERCA) Programme and Generalitat de Catalunya. J.D. received funding from the European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Programme (Grant 677542), and Barts Charity (Grant MGU0343). J.D. was also supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant 107613/Z/15/Z). The authors declare no conflicts of interest.
[+]

Related Items